FDA Panel Votes Against Lilly's Lung Cancer Drug For China-only Trial

A U.S. Food and Drug Administration committee voted against full approval of Eli Lilly and Co.'s lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results were not applicable to U.S. patients. The monoclonal antibody treatment sintilimab injection in combination with pemetrexed and platinum chemotherapy is for the first-line treatment of people

from RTT - Top Story https://ift.tt/Uvex4Tj
via IFTTT